2221010-42-8
Chemical Structure
Dazcapistat
Synonym(s): BLD-2660
- CAS No.: 2221010-42-8
- Formula:C21H18FN3O4
- Molecular Weight:395.38
IUPAC Name: N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-4-(2-fluorophenyl)-2-methyloxazole-5-carboxamide
InChIKey: XYQHCMDVGIJOTA-UHFFFAOYSA-N
SMILES: O=C(C(C(CC1=CC=CC=C1)NC(C2=C(C3=C(F)C=CC=C3)N=C(C)O2)=O)=O)N
Biological Activity: Dazcapistat (BLD-2660) is an orally active small-molecule inhibitor of calpain 1, 2, and 9 (calpain 1, 2, 9). Dazcapistat reduces the expression/production level of IL-6 in injured lung tissue and alleviates fibrosis. Dazcapistat exerts anti-fibrotic effects in various animal models of fibrosis in the skin, liver and lung. Dazcapistat can be used in research related to coronavirus disease 2019 (COVID-19) and idiopathic pulmonary fibrosis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dazcapistat | 98.0% | Dazcapistat (BLD-2660) is an orally active small-molecule inhibitor of calpain 1, 2, and 9 (calpain 1, 2, 9). Dazcapistat reduces the expression/production level of IL-6 in injured lung tissue and alleviates fibrosis. Dazcapistat exerts anti-fibrotic effects in various animal models of fibrosis in the skin, liver and lung. Dazcapistat can be used in research related to coronavirus disease 2019 (COVID-19) and idiopathic pulmonary fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Oliver JC, et al. Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus. Ther Adv Vaccines Immunother. 2022;10:25151355221144845. Published 2022 Dec 23. [Content Brief]
- [2]. Al-Horani RA, et al. Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review. Viruses. 2020;12(10):1092. Published 2020 Sep 26. [Content Brief]
